MwanzoCTSO • NASDAQ
Cytosorbents Corp
$ 0.84
Baada ya Saa za Kazi:
$ 0.85
(1.00%)+0.0084
Imefungwa: 23 Des, 16:28:15 GMT -5 · USD · NASDAQ · Kanusho
HisaHisa zinazouzwa Marekani
Bei iliyotangulia
$ 0.92
Bei za siku
$ 0.81 - $ 0.92
Bei za mwaka
$ 0.70 - $ 1.82
Thamani ya kampuni katika soko
45.72M USD
Wastani wa hisa zilizouzwa
elfu 160.02
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
(USD)Sep 2024Mabadiliko Tangu Mwaka Uliopita
Mapato
9.39M6.58%
Matumizi ya uendeshaji wa biashara
9.61M-24.74%
Mapato halisi
-2.33M74.61%
Kiwango cha faida halisi
-24.8676.17%
Mapato kwa kila hisa
-0.0861.90%
EBITDA
-3.95M41.58%
Asilimia ya kodi ya mapato
Jumla ya mali
Jumla ya dhima
(USD)Sep 2024Mabadiliko Tangu Mwaka Uliopita
Uwekezaji wa pesa taslimu na vipindi vifupi
5.69M-31.99%
Jumla ya mali
47.80M0.48%
Jumla ya dhima
34.80M19.76%
Jumla ya hisa
13.00M
hisa zilizosalia
54.68M
Uwiano wa bei na thamani
3.81
Faida inayotokana na mali
-21.40%
Faida inayotokana mtaji
-26.00%
Mabadiliko halisi ya pesa taslimu
(USD)Sep 2024Mabadiliko Tangu Mwaka Uliopita
Mapato halisi
-2.33M74.61%
Pesa kutokana na shughuli
-2.46M52.73%
Pesa kutokana na uwekezaji
elfu -298.35-15.77%
Pesa kutokana na ufadhili
elfu -99.03-115.27%
Mabadiliko halisi ya pesa taslimu
-2.77M42.13%
Mtiririko huru wa pesa
-1.31M53.63%
Kuhusu
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey. CytoSorbents sells a cytokine adsorbing column — a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful inflammatory mediators like Cytokines, Bilirubin, Myoglobin from the blood. The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as Dialysis, Hemofiltration Cardiopulmonary bypass or ECMO. Other blood purification devices are using different technologies with different performance parameters. This is including polymyxin B hemoperfusion columns, which failed to show significance in a clinical trial for sepsis. The CytoSorb technology has actually the largest body of clinical data confirming safety and efficacy. Clinicaltrials.gov is giving an overview over running research projects. CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins. Wikipedia
Ilianzishwa
1997
Wafanyakazi
186
Gundua zaidi
Huenda unavutiwa na
Orodha hii imetokana na maudhui uliyotafuta hivi majuzi, hisa unazofuatilia na shughuli zingine. Pata maelezo zaidi

Data na maelezo yote hutolewa “kama yalivyo” kwa madhumuni ya taarifa binafsi tu, wala hayanuii kuwa ushauri wa kifedha na hayana madhumuni ya kufanya biashara au uwekezaji, kodi, kisheria, uhasibu au ushauri mwingine. Google si mshauri wa uwekezaji wala mshauri wa kifedha na haitoi maoni au mapendekezo yanayohusiana na kampuni zozote zilizojumuishwa kwenye orodha hii au hisa zozote zilizotolewa na kampuni hizo. Tafadhali wasiliana na dalali wako au mwakilishi wa kifedha ili uthibitishe bei kabla ya kufanya biashara yoyote. Pata maelezo zaidi
Watu pia hutafuta
Tafuta
Futa utafutaji
Funga kisanduku cha kutafutia
Programu za Google
Menyu kuu